TY - JOUR
T1 - Radiofrequency-ablation of unresectable primary and secondary liver tumors: Results in 88 patients
AU - Hildebrand, Philipp
AU - Kleemann, Markus
AU - Roblick, Uwe J.
AU - Mirow, Lutz
AU - Birth, Matthias
AU - Leibecke, Thorsten
AU - Bruch, Hans Peter
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/4
Y1 - 2006/4
N2 - Background and aims: Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. Patients and methods: Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. Results: Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23,9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. Conclusion: RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.
AB - Background and aims: Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. Patients and methods: Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. Results: Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23,9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. Conclusion: RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.
UR - http://www.scopus.com/inward/record.url?scp=33645775741&partnerID=8YFLogxK
U2 - 10.1007/s00423-006-0024-x
DO - 10.1007/s00423-006-0024-x
M3 - Journal articles
C2 - 16604376
AN - SCOPUS:33645775741
SN - 1435-2443
VL - 391
SP - 118
EP - 123
JO - Langenbeck's Archives of Surgery
JF - Langenbeck's Archives of Surgery
IS - 2
ER -